FilingReader Intelligence
Humanwell subsidiary gets Alzheimer's drug approval
July 22, 2025 at 05:11 PM UTC•By FilingReader AI
Yichang Humanwell Pharmaceutical, a subsidiary of Humanwell Healthcare Group, obtained drug registration certificates for its rivastigmine transdermal patch for mild to moderate Alzheimer's disease.
The company invested approximately 19m yuan in research and development for the project. The product generated around 2.6m yuan in national sales in 2024 by other manufacturers.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
SSE:600079•Shanghai Stock Exchange
News Alerts
Get instant email alerts when Humanwell Healthcare Group publishes news
Free account required • Unsubscribe anytime